April 4 (Reuters) - Medical device maker Boston Scientific said on Thursday the U.S. Federal Trade Commission has requested additional information from the company related to the review of its $3.7 billion deal to buy Axonics . (Reporting by Bhanvi Satija in Bengaluru; Editing by Shilpi Majumdar)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
67.55 USD | -0.18% | +0.18% | +8.55% |
May. 16 | Axonics Implant Approved in Australia to Treat Overactive Bladders | MT |
May. 16 | Axonics, Inc. Receives Regulatory Approval for Recharge-Free SNM System in Australia | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
74.66 USD | +0.15% | +1.32% | 110B | ||
67.55 USD | -0.18% | +0.18% | 3.45B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.55% | 3.45B | |
-5.10% | 11.34B | |
+4.02% | 9.11B | |
+38.12% | 5.53B | |
-23.70% | 4.61B | |
-6.44% | 2.87B | |
-5.85% | 2.1B | |
-11.84% | 2.08B | |
-23.36% | 1.78B | |
-9.29% | 1.14B |
- Stock Market
- Equities
- AXNX Stock
- News Axonics, Inc.
- FTC seeks additional information for Boston Scientific's $3.7 bln Axonics deal